RedHill Biopharma (NASDAQ: RDHL) calls March 5 shareholder meeting

Rhea-AI Filing Summary

RedHill Biopharma Ltd. has called an extraordinary general meeting of shareholders for March 5, 2026, to be held at its Tel-Aviv offices. The notice states that only holders of record of ADSs at the close of business on January 23, 2026 are entitled to receive notice and vote.

The board of directors recommends that shareholders vote “FOR” the proposals described in the proxy materials. ADS holders are asked to return their proxies by the deadline on their proxy form, and shareholders may submit written position statements to the company by February 23, 2026.

If a quorum is not reached within half an hour of the scheduled time, the meeting will be adjourned to a later date as determined by the board. The notice and related documents will be available on RedHill’s website and on the SEC website.

 UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

For the month of January 2026

Commission File No.:001-35773

REDHILL BIOPHARMA LTD.

(Translation of registrant’s name into English)

21 Ha'arba'a Street, Tel Aviv, 6473921, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.  

Form 20-F ☒        Form 40-F ☐

Attached hereto and incorporated herein by reference is the notice of the extraordinary general meeting of RedHill Biopharma Ltd. scheduled for March 5, 2026.

This Form 6-K is hereby incorporated by reference into the Company's Registration Statements on Form S-8 filed with the Securities and Exchange Commission on May 2, 2013 (Registration No. 333-188286), on October 29, 2015 (Registration No. 333-207654), on July 25, 2017 (Registration No. 333-219441), on May 23, 2018 (Registration No. 333-225122), on July 24, 2019 (File No. 333-232776), on March 25, 2021 (File No. 333-254692), on May 3, 2021 (File No. 333-255710), on January 11, 2022 (File No. 333-262099), on June 27, 2022 (File No. 333-265845), on June 29, 2023 (File No. 333-273001), on June 20, 2024 (File No. 333-280327) and on March 25, 2025 (File No. 333-286082), and its Registration Statements on Form F-3 filed with the Securities and Exchange Commission on March 30, 2021 (File No. 333-254848), on August 4, 2023 (File No. 333-273709), on October 13, 2023 (File No. 333-274957), as amended, and on August 9, 2024 (File No. 333-281417).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	REDHILL BIOPHARMA LTD.
	(the "Registrant")
Date: January 22, 2026	By:	/s/ Dror Ben-Asher
	Name:	Dror Ben-Asher
	Title:	Chief Executive Officer

REDHILL BIOPHARMA LTD.
21 Ha’arba’a Street

Tel-Aviv 6473921

Israel

NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS

To be held on March 5, 2026

The Extraordinary General Meeting of Shareholders of RedHill Biopharma Ltd. (the “Company”), will be held at the offices of the Company, 21 Ha’arba’a Street, 16^th Floor, Tel-Aviv, Israel, on March 5, 2026, at 3:00 p.m. Israel time, or at any adjournments thereof (the “General Meeting”), for the following purposes:

1. To approve the grant of restricted share units (“RSUs”) each with respect to one American Depository Share (each representing 10,000 ordinary shares, par value NIS 0.01 each) (“ADSs”) to the non-executive directors of the Company;

2. To approve the grant of RSUs to Mr. Dror Ben-Asher, the Company’s Chief Executive Officer and Chairman of the Board of Directors;

3. To approve the grant of RSUs to Mr. Rick D. Scruggs, the Company’s Chief Commercial Officer, and Director; and

4. To approve an increase in the Company’s authorized share capital.

The Company is currently unaware of any other matters that may be raised at the General Meeting. Should any other matters be properly raised at the General Meeting, the persons designated as proxies shall vote according to their own judgment on those matters.

Only holders of record of ADSs, evidenced by American Depositary Receipts issued by The Bank of New York Mellon at the close of business on January 23, 2026, shall be entitled to receive notice of and to vote at the General Meeting. ADS holders should return their proxies by the date set forth on their form of proxy.

The Board of Directors recommends that you vote “FOR” the proposals, as specified on the enclosed form of proxy.

Shareholders wishing to express their position on an agenda item for this General Meeting may do so by submitting a written statement (“Position Statement”) to the Company’s offices, c/o Mr. Razi Ingber, at 21 Ha’arba’a Street, Tel-Aviv, 6473921 Israel, by no later than February 23, 2026. Any Position Statement received, that is in accordance with the guidelines set by the Israel Companies Law, will be furnished to the U.S. Securities and Exchange Commission (the “Commission”) on Form 6-K, and will be made available to the public on the Commission’s website at http://www.sec.gov.

 If within half an hour from the time appointed for the General Meeting a quorum is not present, the General Meeting shall be adjourned to the next business day following the day of the scheduled General Meeting, at the same time and place, or at another day, time and place prescribed by the Board of Directors in a notification to the shareholders.

This Notice and the documents mentioned therein, as well as the proposed resolutions on the agenda, will be made available to the public on the Company's website http://www.redhillbio.com and on the Commission’s website at http://www.sec.gov.

By Order of the Board of Directors,

Dror Ben-Asher

Chairman of the Board of Directors

Tel-Aviv, Israel

January 22, 2026

FAQ

What is RedHill Biopharma (RDHL) announcing in this Form 6-K?

RedHill Biopharma is notifying investors of an extraordinary general meeting of shareholders to be held on March 5, 2026 at its Tel-Aviv offices.

When is the RedHill Biopharma (RDHL) extraordinary general meeting scheduled?

The extraordinary general meeting is scheduled for March 5, 2026, at 3:00 p.m. Israel time, at RedHill’s offices in Tel-Aviv.

Who is entitled to vote at the RedHill Biopharma (RDHL) March 5, 2026 meeting?

Holders of record of ADSs, evidenced by American Depositary Receipts issued by The Bank of New York Mellon, at the close of business on January 23, 2026, are entitled to notice and to vote.

How does the RedHill Biopharma (RDHL) board recommend shareholders vote?

The board of directors recommends that shareholders vote “FOR” the proposals that will be presented at the extraordinary general meeting.

Can RedHill Biopharma (RDHL) shareholders submit position statements for the meeting?

Yes. Shareholders may submit a written Position Statement to the company’s Tel-Aviv offices by February 23, 2026. Qualified statements will be furnished to the SEC on Form 6-K.

What happens if there is no quorum at the RedHill Biopharma (RDHL) meeting?

If a quorum is not present within half an hour of the scheduled start, the meeting will be adjourned to the next business day or another date, time, and place set by the board.

Where can investors find the full RedHill Biopharma (RDHL) meeting materials?

The notice, proposed resolutions, and related documents will be available on www.redhillbio.com and on the SEC’s website at www.sec.gov.